Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People whose prostate has been identified as one that a doctor would consider biopsying
- People aged between 40 and 90 years old
- People with a PSA blood test result of 2.5 or higher
- People who have been fully informed about the study and have signed a consent form agreeing to take part
Who may not be able to join:
- People for whom an MRI scan is not safe or suitable (for example, those with certain metal implants or pacemakers)
- People who have had a prostate biopsy in the past 12 weeks
- People who have a metal implant in the pelvic area, such as a hip replacement, that could interfere with MRI images
- People who have previously had their prostate surgically removed, or who have had other prostate cancer treatments such as cryotherapy, brachytherapy, or radiation to the pelvic area
- People who are currently taking part in another clinical trial involving an investigational drug or device that may affect this study
- People who would be unable to follow the study requirements or attend the required follow-up appointments
- People who have any other condition that the study doctor believes could interfere with the study or make participation not in the person's best interest (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety: no SAEs attributable to the Stratagen Quantitative Prostate MRI Platform, as determined by participating Investigator according to CTCAE guidelines; • Feasibility: collection of the data necessary to produce measurable quantitative T1 and T2 relaxation times (milliseconds) maps (images) for at least 80% of pixels fully contained within the prostate for at least 80% of subjects
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.